Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

MMJ Recs

JULY 30, 2024

Post-Traumatic Stress Disorder (PTSD) is a multifaceted mental health condition triggered by experiencing or witnessing traumatic events, persistently manifesting in symptoms like flashbacks, severe anxiety, and disrupted sleep. Looking ahead, the future of medical cannabis in PTSD treatment hinges on overcoming these challenges.

Therapy 116

Therapy Treatment Clinical Trials Sleep 116

Cannabis Law Report

AUGUST 3, 2021

Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

JULY 8, 2021

These statements relate to future events or future performance. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Treatment 98

Treatment Clinical Trials CBD Patients 98

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

JULY 29, 2021

With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com. Forward-looking statements.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

JUNE 17, 2021

Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. The Brains partnership with DSM Venturing will allow the company to take advantage of strategic partnerships that DSM has developed since their initial inception in 1902.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

Cannabis Law Report

OCTOBER 6, 2021

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally. Forward-looking statements are only predictions. Investor Relations: Evan Veryard.

Clinical Trials 40

Clinical Trials Research and Development Pharmaceutical Events 40

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, 1.69, 95% CI [1.20–2.36])

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

DECEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., Christopher M. Chipman, CPA. Chief Financial Officer. cchipman@virpaxpharma.com 610-727-4597.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Data 40

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. Clinical trial information: NCT03276572 ( [link] ). Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

The Joint Blog

APRIL 17, 2020

This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. However, in some cases, the risks may outweigh even the proven benefits.

Events 48

Events THC Chronic Pain Sleep 48

Cannabis Law Report

AUGUST 12, 2021

Phase IIb clinical trial of COMP360 psilocybin therapy for TRD close to completion. Danielle Schlosser PhD appointed Senior Vice-President, Clinical Innovation, to lead therapist research and training, bringing her clinical experience in behavioural health and expertise in digital health innovation. Business highlights.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

The Joint Blog

JUNE 2, 2020

The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. Adverse events were mostly mild and resolved spontaneously. 9 -THC: 0.5mg, 1mg, or a placebo. ?

Chronic Pain 58

Chronic Pain Clinical Trials Marijuana Safety 58

The Joint Blog

APRIL 21, 2020

This is according to a study published in the Journal of Clinical Medicine Research and epublished by the U.S. For the study researchers with the Nordic Cannabis Research Institute in Denmark reviewed 25 clinical trials assessing the safety and efficacy of CBD in various populations. National Institute of Health.

Clinical Trials 52

Clinical Trials CBD Safety Patients 52

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

JULY 7, 2021

We remain encouraged as we continue our evaluations of MYMD-1 for efficacy and safety – especially as studies continue to suggest we may be able to address many of the concerns that are associated with the current drugs on the market today in these disease areas.”. President, Director and Chief Medical Officer of MyMD. “We 646) 421-9523.

Pharmaceutical 81

Pharmaceutical Data Clinical Trials Research and Development 81

Cannabis Law Report

JULY 14, 2021

ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States , and a lack of safety for the use of the drug under medical supervision. federal law.

Research and Development 81

Research and Development Clinical Trials Events Treatment 81

TheAnswerPage

FEBRUARY 23, 2022

Some clinical studies have evaluated the safety and efficacy of cannabinoid-based medicines for the treatment of autism spectrum disorder (ASD). Some of these studies have shown positive results, but adverse events were also noted. Fletcher S.

Clinical Trials 40

Clinical Trials Events Therapy Sleep 40

Project CBD

FEBRUARY 28, 2023

Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. 17 Excerpted from HerbalGram , the quarterly publication of the American Botanical Council. Accessed July 25, 2021.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JULY 28, 2021

Cepharanthine is on its way to establishing itself as a once per day, oral anti-cancer therapeutic with a well-established safety profile which will pave the way for an expedited clinical development pathway and future partnering opportunities with pharmaceutical companies. ” Next Steps. ” Next Steps. dcohen@pharmadrug.co.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 40

Epilepsy Pharmaceutical Data Clinical Trials 40

Cannabis Law Report

JUNE 15, 2021

Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. The Brains partnership with DSM Venturing will allow the company to take advantage of strategic partnerships that DSM has developed since their initial inception in 1902.

Pharmaceutical 63

Pharmaceutical Clinical Trials Research and Development Events 63

Cannabis Law Report

JANUARY 26, 2022

The Innovation Passport does not reduce the burden of demonstrating that a treatment may be safe and effective, but does provide research organizers with expert advice, patient input, and collaboration throughout the clinical trial design and development process through a product-specific Target Development Profile.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

JANUARY 12, 2022

As Oregon prepares to roll out the nation’s first legal psilocybin-assisted services program, there is a recognized need for the community to track adverse events and measure efficacy. We don’t believe safety and access are opposing polarities that must be constantly balanced.

Research and Development 52

Research and Development Therapy Clinical Trials Safety 52

Cannabis Law Report

JUNE 2, 2021

Aggregate testing results will be reported to the director of the summer camp via safeCircle’s integration with CLEARED4, the Company’s pooled surveillance testing program partner, through CLEARED4’s smartphone-based online health safety management and reporting solution. Testing will be conducted from mid-June through end-July.

Clinical Trials 63

Clinical Trials Therapy Collective Research and Development 63

Cannabis Law Report

JULY 1, 2021

Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. POPLAR will focus on promoting safety, innovation, and equity in psychedelics research, commerce, and therapeutics. Background. The Project. Access to Psychedelic Therapies and Equity in Emerging Psychedelics Industries.

Law 59

Law Policy Research and Development Clinical Trials 59

Cannabis Law Report

JUNE 14, 2022

The partnership will be officially launched at the virtual event: Preparing Europe for Novel Psychedelic-Assisted Therapies taking place on 23rd June, 14:00 – 16:00 CEST. PAREA is coming together to address those challenges and provide evidence-based policy recommendations and expertise to the EU policymakers.

Access 52

Access Therapy Clinical Trials Treatment 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Topical 40

Cannabis Law Report

JANUARY 13, 2020

Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020. Execute NHIE clinical program utilizing an intravenous formulation of cannabidiol. Forward-looking statements. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

The Cannigma

DECEMBER 12, 2022

Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. Iboga safety: Numerous concerns about the safety of iboga have been raised by scientists.

History 119

History Microdosing Research and Development Clinical Trials 119